Navigation Links
Cleveland Clinic Recognizes New Strategies for Creating Vaccines for Avian Flu as a Top Ten Medical Innovation for 2009
Date:11/13/2008

itional information about Novavax is available at http://www.novavax.com and in the Company's various filings with the Securities and Exchange Commission.

Forward-Looking Statement

Statements herein relating to future development results and performance, conditions or strategies and other matters, including expectations regarding product and clinical developments, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act. Novavax cautions that these forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time. Factors that may cause actual results to differ materially from the results discussed in the forward-looking statements or historical experience include risks relating to the early stage of Novavax's product candidates under development; current results may not be predictive of future pandemic results, results of our seasonal influenza vaccine or any other vaccine that we may develop; further testing is required before regulatory approval can be applied for and the FDA may not approve a vaccine even if further trial results are similar to those disclosed previously by the company; uncertainties relating to clinical trials, including possible delays in initiating or completing the trials and safety and efficacy results; dependence on the efforts of third parties; competition for clinical resources and patient enrollment from drug candidates in development by other companies with greater resources and visibility; and risks that we may lack the financial resources and access to capital to fund our operations including further clinical trials. Further information on the factors and risks that could affect Novavax's business, financial conditions and results of operations, is contained in Novavax's filings with the U.S. Securities and Exchange Commission, which are available at '/>"/>

SOURCE Novavax, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Cleveland Clinic-Led Research Uncovers New Mechanism That Heightens Risk of Heart Disease
2. Cleveland+ Region Attracts $318 Million in New Venture Investment in 2007
3. Siemens Signs Multi-Year Agreement With Cleveland Clinic to Deploy Enterprise-Wide Cardiology PACS
4. Cleveland Clinic and Rutgers to Lead Newly Formed Institute for War Wounded
5. University Hospitals Case Medical Center, Cleveland, USA and Cardialysis BV, Rotterdam, the Netherlands Enter Strategic Alliance to Found Cardialysis Cleveland
6. NanoMedicine Summit Returns to Cleveland, September 25-26
7. Cleveland Clinic Recognizes Circulating Tumor Cell Technology as Top Medical Innovation for 2009
8. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
9. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
10. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
11. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... ... August 27, 2015 , ... Capital Edge Consulting , a nationwide ... pleased to announce their ranking as one of the top 5000 companies listed on ... companies across the nation. , “It is truly an honor to be recognized as ...
(Date:8/27/2015)... /PRNewswire/ - Portage Biotech Inc. ("Portage") (OTC Market: ... Holding Company Limited (Biohaven), announced today that dosing ... BHV-0223, a glutamate modulating agent. Biohaven filed an ... obtained clearance from the U.S. Food and Drug ... holds 54% equity interest in Biohaven, a private ...
(Date:8/27/2015)...  Asterias Biotherapeutics, Inc. (NYSE MKT: AST), a leading ... today announced that executives from the company will present ... , Pedro Lichtinger , Chief ... Annual Global Investment Conference on Wednesday, September 10, 2015 ... in New York City . ...
(Date:8/27/2015)... , Aug. 27, 2015 HUYA Bioscience International ... of the Japan Society of HTLV-1, held this week ... The purpose of the Society is to promote research ... development of medical technology and research related to these ... "HUYA is proud to support this prestigious ...
Breaking Biology Technology:Capital Edge Consulting Makes Inc. 5000 List of America’s Fastest-Growing Private Companies 2Capital Edge Consulting Makes Inc. 5000 List of America’s Fastest-Growing Private Companies 3Portage's Biohaven doses first human subject in Phase 1 trial with lead drug candidate BHV-0223 2Portage's Biohaven doses first human subject in Phase 1 trial with lead drug candidate BHV-0223 3Portage's Biohaven doses first human subject in Phase 1 trial with lead drug candidate BHV-0223 4Asterias Biotherapeutics to Present at Upcoming Investor Conferences 2HUYA Bioscience International Sponsors Japan Society Of HTLV-1 Annual Meeting 2HUYA Bioscience International Sponsors Japan Society Of HTLV-1 Annual Meeting 3HUYA Bioscience International Sponsors Japan Society Of HTLV-1 Annual Meeting 4
... and NEW DELHI, India, July 17 ... and the stock market, Daiichi Sankyo,Company, Limited ... (NSE/BSE: Ranbaxy/500359) ("Ranbaxy") reiterate that the agreement,between ... the largest,controlling shareholders of Ranbaxy, is binding ...
... ST. LOUIS, July 17 SAFC Supply ... of the Sigma-Aldrich Group (Nasdaq:,SIAL), announced today ... initiative,designed specifically to assist its customers with ... (EU) regulation for chemicals --,Registration, Evaluation, Authorization ...
... of bacteria to produce hydrogen in a bioreactor, with the ... an article in the August issue of Microbiology Today, ... be used to scavenge precious metals from spent automotive catalysts ... , Hydrogen has three times more potential energy by weight ...
Cached Biology Technology:Daiichi Sankyo and Ranbaxy Confirm Deal Is Binding and Final, Allay Market Rumour and Speculation 2SAFC Supply Solutions Launches REACH-Compliant Products and Support 2SAFC Supply Solutions Launches REACH-Compliant Products and Support 3Fuel from food waste: bacteria provide power 2
(Date:8/25/2015)... BELLEVUE, Wash. , Aug. 25, 2015 /PRNewswire/ ... announced today it will unveil its "Guardian S" snake ... the National Tactical Officers Association Conference on August 30 ... S is the first-ever commercially available energetically autonomous snake ... and in-field trials and is protected by more than ...
(Date:8/20/2015)... ., Aug. 20, 2015 NXT-ID, Inc. (NASDAQ: ... authentication company focused on the growing mobile commerce market ... has joined The Smart Card Alliance and the EMV ... Alliance and the Smart Card Alliance Latin America (SCALA) ... industry peers and thought leaders promoting adoption of smart ...
(Date:8/12/2015)... Aug. 12, 2015   MedNet Solutions , an ... spectrum of clinical research, is proud to announce that ... comprehensive SaaS-based eClinical technology platform, has led the way ... two quarters of 2015.   Q2 2015 and Q1 ... measured by contract value sold in the company,s 15 ...
Breaking Biology News(10 mins):Sarcos to Debut First-of-its-Kind Snake Robot 2Sarcos to Debut First-of-its-Kind Snake Robot 3NXT-ID, Inc. Joins Smart Card Alliance and EMV Migration Forum 2NXT-ID, Inc. Joins Smart Card Alliance and EMV Migration Forum 3NXT-ID, Inc. Joins Smart Card Alliance and EMV Migration Forum 4MedNet Solutions Experiences Explosive Corporate Growth 2
... identified a new species of mysterious beaked whale based on ... in the Indian and Pacific Oceans over the past 50 ... toothed whales distantly related to sperm whales, are found in ... throughout the world,s oceans. "They are rarely seen at ...
... This news release is available in ... in the body, for instance, during development, or when neurons establish ... ,wrong turn, will generally cause disease or developmental disorders. The cells ... which they then repel after a short period of contact. Among ...
... NY) When the foe is a disease-causing microbe, identifying ... to kill or disable it. Research to gain this ... The Price Family Foundation. The gift to Albert Einstein ... of Oklahoma funds a research collaboration to investigate the structural ...
Cached Biology News:Researchers discover rare new species of deep-diving whale 2Sociable receptors: In pairs, in groups or in a crowd 2Sociable receptors: In pairs, in groups or in a crowd 3Price Family Foundation funds research collaboration between Albert Einstein College of Medicine and University of Oklahoma 2Price Family Foundation funds research collaboration between Albert Einstein College of Medicine and University of Oklahoma 3
... are supplied as 10X concentrated solutions. REact Buffer ... of the REact buffers and one 250 microl ... four 1 ml vials of REact 1 Buffer ... four 1 ml vials of REact 3 Buffer ...
... Apoptosis Assay Kit #4 detects apoptosis ... in the permeability of cell membranes. This ... and propidium iodide nucleic acid stains. YO-PRO-1 ... of apoptotic cells and labels them with ...
Porcine TNF-alpha/TNFSF1A ELISpot Development Module...
Request Info...
Biology Products: